Literature DB >> 23485145

Design of hybrid lipid/retroviral-like particle gene delivery vectors.

Rahul K Keswani1, Ian M Pozdol, Daniel W Pack.   

Abstract

Recombinant retroviruses provide highly efficient gene delivery and the potential for stable gene expression. The retroviral envelope protein, however, is the source of significant disadvantages such as immunogenicity, poor stability (half-life of transduction activity of 5-7 h at 37 °C for amphotropic murine leukemia virus), and difficult production and purification. To address these problems, we report the construction of efficient hybrid vectors through the association of murine leukemia virus (MLV)-like particles (M-VLP) with synthetic liposomes comprising DOTAP, DOPE, and cholesterol (φ/M-VLP). We conclude that the lipid composition is a significant determinant of the transfection efficiency and uptake of φ/M-VLP in HEK293 cells with favorable compositions for transfections being those with low DOTAP, low DOPE, and high cholesterol content. Cellular uptake, however, was dependent on DOTAP content alone. By extrusion of liposomes prior to vector assembly, the size of these hybrid vectors could also be decreased to ≈300 nm, as confirmed via DLS and TEM. φ/M-VLP were also robust on storage in terms of vector size and transfection efficiency and provided stable transgene expression over a period of three weeks. We conclude that the noncovalent combination of biocompatible synthetic lipids with inactive retroviral particles to form a highly efficient hybrid vector is a significant extension to the development of novel gene delivery platforms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485145      PMCID: PMC3646931          DOI: 10.1021/mp300561y

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  48 in total

Review 1.  Nonviral gene therapy: promises and challenges.

Authors:  S Li; L Huang
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

2.  Small-volume extrusion apparatus for preparation of large, unilamellar vesicles.

Authors:  R C MacDonald; R I MacDonald; B P Menco; K Takeshita; N K Subbarao; L R Hu
Journal:  Biochim Biophys Acta       Date:  1991-01-30

Review 3.  Large-scale processing of recombinant retroviruses for gene therapy.

Authors:  S T Andreadis; C M Roth; J M Le Doux; J R Morgan; M L Yarmush
Journal:  Biotechnol Prog       Date:  1999 Jan-Feb

4.  Inclusion of cholesterol in DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence of serum.

Authors:  K Crook; B J Stevenson; M Dubouchet; D J Porteous
Journal:  Gene Ther       Date:  1998-01       Impact factor: 5.250

Review 5.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

6.  Effect of serum on transfection by polyethylenimine/virus-like particle hybrid gene delivery vectors.

Authors:  David M Drake; Rahul K Keswani; Daniel W Pack
Journal:  Pharm Res       Date:  2010-08-21       Impact factor: 4.200

7.  Retargeting of viral vectors to the folate receptor endocytic pathway.

Authors:  J A Reddy; D W Clapp; P S Low
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

8.  A novel cationic liposome reagent for efficient transfection of mammalian cells.

Authors:  X Gao; L Huang
Journal:  Biochem Biophys Res Commun       Date:  1991-08-30       Impact factor: 3.575

Review 9.  Rafts, anchors and viruses--a role for glycosylphosphatidylinositol anchored proteins in the modification of enveloped viruses and viral vectors.

Authors:  Christoph Metzner; Brian Salmons; Walter H Günzburg; John A Dangerfield
Journal:  Virology       Date:  2008-10-28       Impact factor: 3.616

Review 10.  Cancer gene therapy clinical trials: lessons for the future.

Authors:  E Galanis; S Russell
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

View more
  9 in total

1.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

Review 2.  Insights into the nuclear export of murine leukemia virus intron-containing RNA.

Authors:  Lucie Pessel-Vivares; Laurent Houzet; Sébastien Lainé; Marylène Mougel
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 3.  Biopolymers augment viral vectors based gene delivery.

Authors:  Balaji Balakrishnan; Ernest David
Journal:  J Biosci       Date:  2019-09       Impact factor: 1.826

4.  Intracellular trafficking of hybrid gene delivery vectors.

Authors:  Rahul K Keswani; Mihael Lazebnik; Daniel W Pack
Journal:  J Control Release       Date:  2015-04-14       Impact factor: 9.776

5.  A model for targeting colon carcinoma cells using single-chain variable fragments anchored on virus-like particles via glycosyl phosphatidylinositol anchor.

Authors:  Vipin Kumar Deo; Megumi Yui; Jahangir Alam; Masahito Yamazaki; Tatsuya Kato; Enoch Y Park
Journal:  Pharm Res       Date:  2014-02-26       Impact factor: 4.200

6.  Efficient in vitro gene delivery by hybrid biopolymer/virus nanobiovectors.

Authors:  Rahul Keswani; Kai Su; Daniel W Pack
Journal:  J Control Release       Date:  2014-07-08       Impact factor: 9.776

Review 7.  Exploiting virus-like particles as innovative vaccines against emerging viral infections.

Authors:  Hotcherl Jeong; Baik Lin Seong
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

8.  Transfection types, methods and strategies: a technical review.

Authors:  Zhi Xiong Chong; Swee Keong Yeap; Wan Yong Ho
Journal:  PeerJ       Date:  2021-04-21       Impact factor: 2.984

Review 9.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.